Zoetis Inc. (ZTS) |
|
166.44 2.29 (1.4%)
|
03-31 16:05 |
|
Open: |
165.1 |
Pre. Close: |
164.15 |
|
High:
|
166.49 |
Low:
|
164.03 |
|
Volume:
|
1,705,002 |
Market Cap:
|
77,126(M) |
|
|
|
Technical analysis |
as of: 2023-03-31 4:23:26 PM |
|
Overall:
|
  |
| Stoxline posted a STRONG BUY today, upgraded from lower rating. Upward movement to be expected. |
| Target: |
Six months: 200.87 One year: 234.61 |
| Support: |
Support1: 164.21 Support2: 159.41 |
| Resistance: |
Resistance1: 171.97 Resistance2: 200.87 |
| Pivot: |
164.34 |
| Moving Average: |
MA(5): 164.79 MA(20): 164.97 
MA(100): 157.77 MA(250): 162.6 |
| MACD: |
MACD(12,26): -0.4 Signal(9): -0.4 |
| Stochastic oscillator: |
%K(14,3): 53.4 %D(3): 47.7 |
| RSI: |
RSI(14): 52.7 |
| 52-week: |
High: 201.32 Low: 124.15 |
| Average Vol(K): |
3-Month: 2,133 (K) 10-Days: 1,663 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ZTS ] has closed below upper band by 18.2%. Bollinger Bands are 62.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 5 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
166.64 - 167.29 |
167.29 - 168.02 |
|
Low:
|
162.27 - 162.96 |
162.96 - 163.76 |
|
Close:
|
165.09 - 166.21 |
166.21 - 167.5 |
|
Company Description |
|
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey. |
Headline News |
Fri, 31 Mar 2023
Terra Nova Asset Management LLC Has $1.71 Million Stock ... - MarketBeat
Thu, 30 Mar 2023
Zoetis to Host Webcast and Conference Call on First Quarter 2023 Financial Results - Yahoo Finance
Thu, 30 Mar 2023
Guru Fundamental Report for ZTS - Nasdaq
Wed, 29 Mar 2023
Vestmark Advisory Solutions Inc. Trims Stock Holdings in Zoetis Inc ... - MarketBeat
Sun, 26 Mar 2023
Perfromance Wealth Partners LLC Sells 11990 Shares of Zoetis Inc ... - MarketBeat
Sat, 25 Mar 2023
Congress Asset Management Co. MA Reduces Its Holdings in ... - Best Stocks
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Outperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NYSE |
| Sector: Healthcare |
| Industry: Drug Manufacturers—Specialty & Generic |
| Shares Out. |
463 (M) |
| Shares Float |
463 (M) |
|
% Held by Insiders
|
0.2 (%) |
|
% Held by Institutions
|
94.4 (%) |
|
Shares Short
|
4,240 (K) |
|
Shares Short P.Month
|
4,190 (K) |
Stock Financials |
|
EPS
|
4.51 |
|
EPS Est Next Qtl
|
0.64 |
|
EPS Est This Year
|
2.33 |
|
EPS Est Next Year
|
2.68 |
|
Book Value (p.s.)
|
9.5 |
|
Profit Margin (%)
|
26.1 |
|
Operating Margin (%)
|
36.3 |
|
Return on Assets (ttm)
|
12.7 |
|
Return on Equity (ttm)
|
47.1 |
|
Qtrly Rev. Growth
|
3.7 |
|
Gross Profit (p.s.)
|
12.14 |
|
Sales Per Share
|
17.43 |
|
EBITDA (p.s.)
|
7.18 |
|
Qtrly Earnings Growth
|
12.5 |
|
Operating Cash Flow
|
1,910 (M) |
|
Levered Free Cash Flow
|
1,170 (M) |
Stock Valuations |
|
PE Ratio
|
36.81 |
|
PEG Ratio
|
2.8 |
|
Price to Book value
|
17.51 |
|
Price to Sales
|
9.54 |
|
Price to Cash Flow
|
40.36 |
Stock Dividends |
|
Dividend
|
0.37 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0.2% |
|
Dividend Pay Date
|
2022-02-28 |
|
Ex-Dividend Date
|
2022-01-18 |
|
Your Ad Here
|
|
